Cargando…

Potential Benefits of Neoadjuvant Chemotherapy in Clinically Node-Positive Luminal Subtype(−) Breast Cancer

PURPOSE: Neoadjuvant chemotherapy (NAC) is less effective for luminal breast cancer because luminal breast cancer has a lower rate of pathological complete response (pCR) after NAC than human epidermal growth factor receptor 2 (HER2)-type and triple-negative breast cancer (TNBC). We investigated the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hyung Suk, Yoo, Tae Kyung, Park, Woo Chan, Chae, Byung Joo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Breast Cancer Society 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769389/ https://www.ncbi.nlm.nih.gov/pubmed/31598341 http://dx.doi.org/10.4048/jbc.2019.22.e35

Ejemplares similares

Improved Model for Predicting Axillary Response to Neoadjuvant Chemotherapy in Patients with Clinically Node-Positive Breast Cancer
por: Kim, Hyung Suk, et al.
Publicado: (2017)

Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response
por: Thompson, Kevin J, et al.
Publicado: (2022)

Efficacy of chemotherapy for lymph node-positive luminal A subtype breast cancer patients: an updated meta-analysis
por: Li, Yilun, et al.
Publicado: (2020)

Omission of Chemotherapy for the Treatment of Mucinous Breast Cancer: A Nationwide Study from the Korean Breast Cancer Society
por: Kim, Hyung Suk, et al.
Publicado: (2019)

Young Age Is Associated with Increased Locoregional Recurrence in Node-Positive Breast Cancer with Luminal Subtypes
por: Kim, Sang-Won, et al.
Publicado: (2017)

Clinical Differences in Triple-Positive Operable Breast Cancer Subtypes in Korean Patients: An Analysis of Korean Breast Cancer Registry Data
por: You, Sun Hyong, et al.
Publicado: (2018)

Assessment of axillary node status by ultrasound after neoadjuvant chemotherapy in patients with clinically node-positive breast cancer according to breast cancer subtype
por: Maeshima, Yurina, et al.
Publicado: (2021)

Discrepancy of Breast and Axillary Pathologic Complete Response and Outcomes in Different Subtypes of Node-positive Breast Cancer after Neoadjuvant Chemotherapy
por: Chen, Shin-Cheh, et al.
Publicado: (2021)

Is Pathologic Axillary Staging Valid If Lymph Nodes Are Less than 10 with Axillary Lymph Node Dissection after Neoadjuvant Chemotherapy?
por: Choi, Hee Jun, et al.
Publicado: (2022)

Predictors of axillary node response in node-positive patients undergoing neoadjuvant chemotherapy for breast cancer
por: Ladak, Farah, et al.
Publicado: (2022)

Is adjuvant chemotherapy better than neoadjuvant chemotherapy for those with node positive disease?
por: Zabell, Joseph, et al.
Publicado: (2018)

The Prognosis and the Role of Adjuvant Chemotherapy for Node-Positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Surgery
por: Jeong, Hyehyun, et al.
Publicado: (2022)

Impact of Immunohistochemistry-Based Molecular Subtype on Chemosensitivity and Survival in Patients with Breast Cancer Following Neoadjuvant Chemotherapy
por: Yoo, Changhoon, et al.
Publicado: (2012)

Use of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Patients with Axillary Node-Positive Breast Cancer in Diagnosis
por: Choi, Hee Jun, et al.
Publicado: (2018)

The Prognostic Value of Lymph Node Involvement after Neoadjuvant Chemotherapy Is Different among Breast Cancer Subtypes
por: Laot, Lucie, et al.
Publicado: (2021)

Predicting the Response of Neoadjuvant Chemotherapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer With Axillary Lymph Node Metastasis by Multigene Assay
por: Lee, Jun-Hee, et al.
Publicado: (2022)

The Neutrophil to Lymphocyte Ratio Predicts the Response to Neoadjuvant Chemotherapy in Luminal B Breast Cancer
por: Rivas, Mauricio, et al.
Publicado: (2019)

BCL2 as a Subtype-Specific Prognostic Marker for Breast Cancer
por: Eom, Yong Hwa, et al.
Publicado: (2016)

Prediction of axillary response after neoadjuvant chemotherapy in clinical node positive breast cancer
por: Zheng, Weizhen, et al.
Publicado: (2021)

The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy
por: Straver, M. E., et al.
Publicado: (2010)

Accuracy and Limitations of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients with Positive Nodes
por: Aragon-Sanchez, Sofia, et al.
Publicado: (2022)

The Benefit of Post-Mastectomy Radiotherapy in ypN0 Patients after Neoadjuvant Chemotherapy According to Molecular Subtypes
por: Cho, Won Kyung, et al.
Publicado: (2019)

Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer
por: Zhang, Zhuo, et al.
Publicado: (2021)

Relation Between Tumor Size and Lymph Node Metastasis According to Subtypes of Breast Cancer
por: Min, Seung Ki, et al.
Publicado: (2021)

Non-sentinel node metastasis prediction during surgery in breast cancer patients with one to three positive sentinel node(s) following neoadjuvant chemotherapy
por: Chun, Jung Whan, et al.
Publicado: (2023)

Clinical scenarios for neoadjuvant chemotherapy of squamous penile cancer that is clinically node positive
por: Fishman, Mayer N.
Publicado: (2017)

The Radiological Response Rate Pattern Is Associated With Recurrence Free Survival in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Ahn, Juneyoung, et al.
Publicado: (2022)

Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer
por: Kim, Hee Jeong, et al.
Publicado: (2020)

Nomogram for accurate prediction of breast and axillary pathologic response after neoadjuvant chemotherapy in node positive patients with breast cancer
por: Choi, Hee Jun, et al.
Publicado: (2019)

Nomogram for predicting axillary lymph node pathological response in node-positive breast cancer patients after neoadjuvant chemotherapy
por: Wang, Wenyan, et al.
Publicado: (2022)

Response to neoadjuvant chemotherapy based on pathologic complete response in very young patients with ER-positive breast cancer: a large, multicenter, observational study
por: Woo, Joohyun, et al.
Publicado: (2021)

Prognostic Nomogram for Prediction of Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy in Cytologically Proven Node-Positive Breast Cancer
por: Kim, Jee Ye, et al.
Publicado: (2015)

Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer
por: Lukey, Michael J., et al.
Publicado: (2019)

ABTB2 Regulatory Variant as Predictor of Epirubicin-Based Neoadjuvant Chemotherapy in Luminal A Breast Cancer
por: Gong, Yajie, et al.
Publicado: (2020)

Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2022)

Adjuvant endocrine therapy alone in patients with node-positive, luminal A type breast cancer
por: Park, Sungmin, et al.
Publicado: (2017)

Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
por: Gwark, Sungchan, et al.
Publicado: (2021)

Impact of Molecular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical Outcome
por: Lim, Siew Kuan, et al.
Publicado: (2016)

Oncologic efficacy of gonadotropin-releasing hormone agonist in hormone receptor-positive very young breast cancer patients treated with neoadjuvant chemotherapy
por: Choi, Hee Jun, et al.
Publicado: (2023)

Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses
por: Yang, Yaewon, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hir6i6q5liuq293gt5vfu8qncg